Determination of the Clinical Impact of Continuous Surveillance Monitoring (SM) and Utility of IPI. (IPI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03050983|
Recruitment Status : Completed
First Posted : February 13, 2017
Last Update Posted : September 30, 2020
|Condition or disease||Intervention/treatment|
|Respiratory Depression Respiratory Insufficiency||Device: IPI|
|Study Type :||Observational|
|Actual Enrollment :||440 participants|
|Official Title:||Observational Investigation to Determine Clinical Impact of Continuous Surveillance Monitoring (SM) on General Care Floors With a Nested Study to Determine the Clinical Utility of IPI (Integrated Pulmonary Index).|
|Actual Study Start Date :||February 15, 2017|
|Actual Primary Completion Date :||January 26, 2018|
|Actual Study Completion Date :||September 10, 2020|
Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
Enable the IPI algorithm and IPI alarm algorithm
Other Name: Integrated Pulmonary Index (IPI)
- Clinical Utility of IPI and IPI Alarm [ Time Frame: Not to exceed nine months of observation ]Adjusted Hospital Length of Stay in both Phases
- Clinical Impact of continuous surveillance capnography and pulse oximetry monitoring [ Time Frame: Not to exceed 24 months of reported escalation of care events to the Principal Investigator ]Number of alarms per patient, number of rapid response team activation, number of intensive care unit escalation and hospital cost per patient in each Phase.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03050983
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37212|
|Principal Investigator:||Liza Weavind, MBBCh,FCCM,MMHC||Vanderbilt University Medical Center|